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Abstract: The recent data reported by Tang and colleagues in Science Translational Medicine suggest that alpha-2 
adrenoceptors (α2AAR) genetic heterogeneity may explain diverging results regarding the effects of α2AAR 
antagonists on insulin secretion and glucose control in patients with type 2 diabetes. They first confirmed that the 
risk variant for rs553668 (the A allele for a single-nucleotide polymorphism in ADRA2A) is likely to cause defective 
insulin secretion in human pancreatic islets. Second they showed that blocking α2AAR with yohimbine dose-
dependently improves the reduced insulin secretion during an oral glucose tolerance test in patients with the risk 
variant. The successful translation of genomic information into clinical intervention in patients with type 2 diabetes 
provides proof of concept for the feasibility of individualized treatment based on genotype.
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Type 2 diabetes mellitus is associated with an alarming 
rise in the incidence worldwide and is among the most 
challenging health issues of the 21st century. It is associated 
with a markedly increased risk of vascular complications, 
which impair quality of life and reduce life expectancy. 
Consequently the prevention and treatment of type 2 
diabetes is a key objective from a public health point of 
view. Type 2 diabetes is recognized to be a heterogeneous 
complex disease. This polygenic disorder is largely 
influenced by life-style factors among which poor food 
habits and lack of physical exercise play a major role (1). 
Glucose metabolism is normally regulated by a feedback 
loop including islet beta cells and insulin-sensitive tissues, 
in which tissue sensitivity to insulin affects magnitude of 
β-cell response (1). When beta cells cannot release sufficient 
insulin to compensate for insulin resistance, plasma glucose 
concentrations are rising. Because several mechanisms, 
including lifestyle, in addition to genetic risk variants 
contribute to the disease, the feasibility of genotype-based 
personalized treatment for a complex polygenic disorder 
like type 2 diabetes has been debated (1). The development 
of genetics allows the characterization of more specific 
subgroups of patients with diabetes, especially those initially 
included in the group of type 2 diabetes such patients 
with monogenic Maturity Onset of Diabetes of the Young 
(MODY). However, cases of monogenic diabetes with 
autosomal dominant inheritance are relatively rare, and 
most patients with type 2 diabetes rather have a polygenic 
background (1). 
Numerous pharmacologic approaches have been 
developed in recent years for the management of 
hyperglycemia in type 2 diabetes and the best choice 
after failure of metformin monotherapy is becoming 
increasingly difficult for the physician (2). In a recent 
sys temat ic  rev iew,  ev idence  of  pharmacogenet ic 
interactions was found for most oral glucose-lowering 
agents such as metformin, sulfonylureas, repaglinide, 
thiazolidinediones, and acarbose (3). These promising 
results show the potential of using genetic variation to 
tailor therapy for type 2 diabetes although most reported 
examples concern pharmacokinetics interactions. A recent 
example has been described for metformin, the first-line 
medication for the management of hyperglycemia in type 
2 diabetes (2). It has been shown that the genetic variants 
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of organic cation transporters (OCTs) may influence 
the pharmacokinetics and as a consequence the glucose-
lowering response to the drug (4). While high-quality 
controlled studies with prespecified analyses are still 
lacking, preliminary available results bring the promise of 
personalized medicine in type 2 diabetes one step closer to 
success (3). 
Whereas type 2 diabetes is characterized by both insulin 
resistance and defective insulin secretion, an increasing set 
of data suggests that the defect in insulin secretion plays 
a prominent role in the development and progression of 
hyperglycemia (5). Although environmental changes play 
an essential part, beta-cell dysfunction has a clear genetic 
component (1). Much interest exists in finding medications 
that can ameliorate the function of beta cell to improve 
glucose homeostasis. One major objective is the protection 
of beta cell to avoid its progressive loss of function that 
largely explains the almost ineluctable deterioration of 
glucose control with time that is commonly observed in 
patients with type 2 diabetes.
The physiologic mechanisms of glucose-induced 
insulin secretion are well understood. By closing ATP-
sensitive K+ [K(ATP)] channels, glucose promotes 
depolarization-dependent Ca2+ entry and cytoplasmic free 
Ca2+ concentration rise in beta cells, leading to activation 
of the exocytotic machinery and glucose-dependent 
insulin secretion. Thus, K(ATP) channels in beta cells 
are a major target for insulinotropic drugs. Enhancing 
insulin secretion can be obtained using sulfonylureas (or 
glinides), compounds that directly close K(ATP) channels 
of the beta cells independently of ambient glucose 
concentration. These compounds are commonly used for 
the management of type 2 diabetes for several decades. 
Despite the launch of new pharmacologic approaches, 
they still occupy a major place to control hyperglycemia 
in type 2 diabetes (2). However, as sulfonylureas stimulate 
insulin secretion blindly of ambient glucose, they are 
associated with an increased risk of hypoglycemia. Some 
genetic variants have been reported, which may affect both 
pharmacokinetics and pharmacodynamics of sulfonylureas 
and repaglinide (3). As an example, the GoDARTs study 
investigated the effect of TCF7L2 rs12255372 and 
rs7903146 genotypes on glycemic response in patients 
with type 2 diabetes and showed that variation in TCF7L2 
influences therapeutic response to sulfonylureas but 
not metformin. Thus, this study establishes that genetic 
variation can alter response to sulfonylurea therapy in type 
2 diabetes (6). To what extent such genetic variation may 
contribute to the between-subject variability in glucose-
lowering effect and in the risk of hypoglycemia remains, 
however, to be investigated.
The most remarkable genotype-based therapy in diabetes 
field concerns the use of sulfonylureas in patients with 
neonatal diabetes (7). Heterozygous activating mutations 
in KCNJ11, encoding the Kir6.2 subunit of the K(ATP) 
channel, cause around half of cases of diabetes diagnosed in 
patients under 6 months of age. These children present with 
ketoacidosis or severe hyperglycemia and were classically 
treated with insulin. In these young patients, diabetes results 
from impaired insulin secretion caused by a failure of the 
beta-cell K(ATP) channel to close in response to increased 
intracellular ATP. Because sulfonylureas close the K(ATP) 
channel by an ATP-independent route, sulfonylurea therapy 
is remarkably effective (more than insulin indeed) for patients 
with diabetes caused by KCNJ11 mutations (7).
More recently, new agents that can enhance insulin 
secretion by targeting the glucagon-like peptide-1 
(GLP-1) receptor present in the beta cells have been 
developed with the commercialization of specific 
inhibitors of dipeptidyl peptidase-4 (DPP-4), an enzyme 
that degrades GLP-1 into inactive products, or injectable 
GLP-1 receptor agonists resistant to the action of DPP-
4 (2). These so-called incretin-based therapies potentiate 
insulin secretion in a glucose-dependent manner and 
thus rarely cause hypoglycemia, which represents an 
obvious advantage in clinical practice compared to 
sulfonylureas (2). No special mention of incretin-
based therapies could be found in a review about 
pharmacogenetics of type 2 diabetes (3). However, it 
has been recently shown that the CTRB1/2 locus, a 
known diabetes risk locus, not only affects diabetes 
susceptibi l i ty but also treatment via the incretin 
pathway (8). Indeed, rs7202877 near CTRB1/2 associated 
with a lower glycated hemoglobin (HbA1c) response 
to DPP-4 inhibitor treatment in G allele carriers (8). 
In another study, polymorphisms in the transcription 
factor 7-like 2 (TCF7L2) gene were associated with 
type 2 diabetes and reduced insulin secretion and variants 
of TCF7L2 specifically impaired GLP-1-induced insulin 
secretion (9).
Besides targeting K(ATP) channel or GLP-1 receptor, 
another possibility to enhance insulin secretion is the 
modulation of the adrenergic effects on the β cells 
(Figure 1). Already in the seventies, stimulation of α-2 
adrenoceptors (α2AAR) on pancreatic β cells was found 
to inhibit insulin secretion, whereas stimulation of β-2 
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adrenoceptors was found to enhance insulin secretion (10). 
Some studies have shown that certain α2AAR antagonists 
are able to enhance the rate of insulin secretion when 
administered to experimental animals, human volunteers 
or patients with type 2 diabetes or when added to isolated 
islets of Langerhans incubated in vitro (11). These 
effects have been attributed to blockade of islet α2AAR 
leading to an increase in insulin secretion by virtue of 
the relief of the inhibitory tone mediated by endogenous 
catecholamines (10). Based on these findings, it has been 
postulated that α2AAR antagonists could have potential 
in the treatment of type 2 diabetes. This concept has led 
to testing α2AAR antagonists as putative antidiabetic 
agents (12). A few previous studies have investigated insulin 
secretion after α2AAR antagonism. Most of them are of 
small size, and the results are conflicting. As an example, 
the selective α2AAR antagonist idazoxan did not improve 
glucose-induced insulin secretion in healthy subjects nor did 
it improve the impaired first phase of insulin secretion in 
low insulin responders and patients with type 2 diabetes (13). 
As a consequence, no antidiabetic drug targeting beta-cell 
α2AAR is commercialized so far. The recent data reported 
by Tang and colleagues in Science Translational Medicine (14) 
suggest that α2AAR genetic heterogeneity might underlie 
the diverging results from previous studies.
ADRA2A encodes the α2AAR, which modulates 
adrenergic suppression of insulin secretion. A genetic 
variant in ADRA2A has been shown to be associated with 
defective beta-cell function (15). In man, the A allele for a 
single-nucleotide polymorphism, rs553668, in ADRA2A was 
associated with reduced glucose-stimulated insulin secretion 
and increased type 2 diabetes risk, a finding replicated in 
several Caucasian cohorts (15-17). The ADRA2A genetic 
variation may affect baseline insulin concentrations 
in healthy individuals and the insulin decrease after 
administration of dexmedetomidine, a selective α2AAR 
agonist (18). On the contrary, the α2AAR antagonist 
yohimbine has been shown to enhance insulin release 
in vitro in islets from organ donors carrying the risk allele to 
levels similar to those in nonrisk carriers (15). In islets from 
donors not carrying the risk allele, yohimbine was without 
effect, indicating that yohimbine specifically counteracts the 
secretion defect associated with the ADRA2A risk allele (15).
Tang and colleagues first confirmed that the risk variant 
for rs553668 is likely to cause defective insulin secretion 
in human pancreatic islets because of an overexpression of 
ADRA2A [10]. These results demonstrate that exaggerated 
α2AAR signaling contributes to the pathophysiology in type 
2 diabetes patients. This is an important finding because 
almost 40% of type 2 diabetes patients carry the risk variant 
for rs553668 (although only around 4% of type 2 diabetes 
patients appears to be homozygous for the risk allele). 
Second they showed that blocking α2AAR with yohimbine 
dose-dependently improves the reduced insulin secretion 
during an oral glucose tolerance test in patients with the risk 
variant. Patients with the risk variant had 25% lower insulin 
secretion at 30 min after the glucose load than those without 
risk genotype. After administration of 20 mg of yohimbine, 
insulin secretion at 30 min was enhanced by 29% in the 
risk group, making secretion similar to patients carrying 
the low-risk allele [10]. The beneficial effect of yohimbine 
was not a consequence of improved insulin sensitivity. 
Thus, defective insulin secretion in diabetic individuals 
carrying the rs553668 risk allele can be corrected by α2AAR 
antagonism. These findings represent the first example of 
pharmacologic targeting of a specific disease mechanism 
for type 2 diabetes coupled to a common genetic variant. 
As a consequence, blocking α2AAR signaling may be a new 
therapeutic means to specifically target the beta-cell defect 
in a rather large proportion of type 2 diabetes patients who 
carry the risk variant for rs553668 (19).
The successful translation of genomic information into 
clinical intervention in diabetic patients provides proof of 
concept for the feasibility of individualized treatment based 
on genotype. Until now, most examples of a significant 
influence of pharmacogenetics in type 2 diabetes concern 
changes in pharmacokinetics, which may subsequently 
Figure 1 Pharmacologic approaches enhancing insulin secretion by 
the beta cells using different cellular targets and pharmacogenetic 
influences that can alter the glucose-lowering response to oral 
agents able to stimulate insulin secretion. ADRA2A, gene that 
encodes the α2AAR; α2AAR, alpha-2 adrenoceptor; GLP-1 R, 
glucagon-like peptide-1 receptor; Kir6.2/SUR1, sulfonylurea 
receptor subunit (SUR) of the ATP-sensitive K(+) (KATP) channel.
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translate to pharmacodynamic changes (3,4). Genetic risk 
variants can be used to guide therapeutic interventions 
tailored to the individual patient in the future. Tang et al. 
tested yohimbine because it has been used clinically for 
other indications and is well characterized. For long-term 
clinical use, other α2AAR antagonists with less central 
effects would probably be preferred to avoid adverse 
events. Several other α2AAR antagonists exist and should 
be investigated in type 2 diabetes according to this new 
genotype-based opportunity. Nevertheless, because α2AAR 
are present in several tissues and organs, its antagonism 
may potentially cause undesired adverse effects, especially 
regarding the cardiovascular system.
More generally,  a patient-centered approach is 
recommended for the management of type 2 diabetes. 
After metformin therapy, and according to the recently 
updated joint American Diabetes Association (ADA)-
European Association for the Study of Diabetes (EASD) 
position statement (2), the physician has the choice between 
six glucose-lowering strategies: adding a sulfonylurea, a 
glitazone, a DPP-4 inhibitor, a sodium-glucose cotransporter 
type 2 (SGLT2) inhibitor, a GLP-1 receptor agonist or basal 
insulin. The choice is based upon simple key-features such 
as glucose-lowering effect (efficacy), risk of hypoglycemia, 
body weight changes, overall safety and cost. The future 
will probably see the development of new approaches that 
may help the physician in selecting the best responders to 
a specific drug using a genotype-based approach besides 
other classic and phenotype-based strategies. Although 
pharmacogenomics can explain some of the heterogeneity in 
dose requirements, response and incidence of adverse effects 
of drugs between individuals, it is now clearly understood 
that much of the diversity in drug effects cannot be solely 
explained by studying the genomic diversity in patients with 
type 2 diabetes. Epigenomics, the field that focuses on non-
genomic modifications that influence gene expression, may 
expand the scope of pharmacogenomics towards optimization 
of drug therapy and the realization of personalized 
medicine (20). Future individualized treatment of type 
2 diabetes should involve a combination of therapeutic 
strategies, including genotype-based approaches, besides life-
style modifications, in order to enhance insulin secretion (as 
discussed in this paper) and reduce insulin resistance, the two 
key defects of type 2 diabetes mellitus. 
Acknowledgements
Disclosure: The author declares no conflict of interest.
References
1. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and 
treatment of type 2 diabetes: perspectives on the past, 
present, and future. Lancet 2014;383:1068-83.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management 
of hyperglycemia in type 2 diabetes, 2015: a patient-
centered approach: update to a position statement of 
the American Diabetes Association and the European 
Association for the Study of Diabetes. Diabetes Care 
2015;38:140-9. 
3. Maruthur NM, Gribble MO, Bennett WL, et al. The 
pharmacogenetics of type 2 diabetes: a systematic review. 
Diabetes Care 2014;37:876-86.
4. Scheen AJ. Personalising metformin therapy: a clinician's 
perspective.Lancet Diabetes Endocrinol. 2014;2:442-4.
5. Halban PA, Polonsky KS, Bowden DW, et al. β-cell 
failure in type 2 diabetes: postulated mechanisms and 
prospects for prevention and treatment. Diabetes Care 
2014;37:1751-8.
6. Pearson ER, Donnelly LA, Kimber C, et al. Variation in 
TCF7L2 influences therapeutic response to sulfonylureas: 
a GoDARTs study. Diabetes 2007;56:2178-82.
7. Pearson ER, Flechtner I, Njølstad PR, et al. Switching 
from insulin to oral sulfonylureas in patients with diabetes 
due to Kir6.2 mutations. N Engl J Med 2006;355:467-77.
8. 't Hart LM, Fritsche A, Nijpels G, et al. The CTRB1/2 
locus affects diabetes susceptibility and treatment via the 
incretin pathway. Diabetes 2013;62:3275-81.
9. Schäfer SA, Tschritter O, Machicao F, et al. Impaired 
glucagon-like peptide-1-induced insulin secretion in 
carriers of transcription factor 7-like 2 (TCF7L2) gene 
polymorphisms. Diabetologia 2007;50:2443-50. 
10. Robertson RP, Halter JB, Porte D Jr. A role for alpha-
adrenergic receptors in abnormal insulin secretion in 
diabetes mellitus. J Clin Invest 1976;57:791-5.
11. Abdel-Zaher AO, Ahmed IT, El-Koussi AD. The potential 
antidiabetic activity of some alpha-2 adrenoceptor 
antagonists. The potential antidiabetic activity of some 
alpha-2 adrenoceptor antagonists. Pharmacol Res 
2001;44:397-409.
12. Broadstone VL, Pfeifer MA, Bajaj V, et al. Alpha-
adrenergic blockade improves glucose-potentiated insulin 
secretion in non-insulin-dependent diabetes mellitus. 
Diabetes 1987;36:932-7.
13. Ostenson CG, Pigon , Doxey JC, et al. Alpha 
2-adrenoceptor blockade does not enhance glucose-
induced insulin release in normal subjects or patients with 
Annals of Translational Medicine, Vol 3, Suppl 1 May 2015 Page 5 of 5
© Annals of Translational Medicine. All rights reserved. Ann Transl Med 2015;3(S1):S36www.atmjournal.org
noninsulin-dependent diabetes. J Clin Endocrinol Metab 
1988;67:1054-9.
14. Tang Y, Axelsson AS, Spégel P, et al. Genotype-based 
treatment of type 2 diabetes with an α2A-adrenergic 
receptor antagonist. Sci Transl Med 2014;6:257ra139.
15. Rosengren AH, Jokubka R, Tojjar D, et al. Overexpression 
of alpha2A-adrenergic receptors contributes to type 2 
diabetes. Science 2010;327:217-20.
16. Långberg EC, Seed Ahmed M, Efendic S, et al. Genetic 
association of adrenergic receptor alpha 2A with obesity and 
type 2 diabetes. Obesity (Silver Spring) 2013;21:1720-5. 
17. Bo S, Cassader M, Cavallo-Perin P, et al. The rs553668 
polymorphism of the ADRA2A gene predicts the 
worsening of fasting glucose values in a cohort of subjects 
without diabetes. A population-based study. Diabet Med 
2012;29:549-52.
18. Ghimire LV, Muszkat M, Sofowora GG, et al. Variation 
in the α(2A) adrenoceptor gene and the effect of 
dexmedetomidine on plasma insulin and glucose.
Pharmacogenet Genomics 2013;23:479-86. 
19. Liggett SB. alpha2A-adrenergic receptors in the genetics, 
pathogenesis, and treatment of type 2 diabetes. Sci Transl 
Med 2009;1:12ps15.
20. Manolopoulos VG, Ragia G, Tavridou A. 
Pharmacogenomics of oral antidiabetic medications: 
current data and pharmacoepigenomic perspective. 
Pharmacogenomics 2011;12:1161-91.
Cite this article as: Scheen AJ. Towards a genotype-based 
approach for a patient-centered pharmacologic therapy of type 
2 diabetes. Ann Transl Med 2015;3(S1):S36. doi: 10.3978/
j.issn.2305-5839.2015.03.56
